Search bioRxiv⌕ Search

Biology subjects

Hana, T.

Publications and source records attributed to Hana, T..

3 recordsLinked to original sources

Vaccination targeting the novel endogenous tumor-associated antigen Gpr149 induces protective immunity against checkpoint inhibitor-refractory SB28 glioblastoma

Background: Glioblastoma is a lethal brain tumor notable for its limited spontaneous induction of CD8+ T cell responses. Vaccination may overcome this limitation by generating tumor-specific CD8+ T cells capable of mediating anti-tumor immunity in the brain. However, preclinical vaccine development is constrained by a lack of immunologically stringent glioblastoma models with defined endogenous antigens. We therefore sought to identify endogenous, vaccine-targetable antigens expressed by the immune checkpoint-refractory SB28 syngeneic mouse glioblastoma model and to evaluate their targetability using a heterologous prime-boost regimen with the chimpanzee adenovirus ChAdOx1 and the modified vaccinia Ankara (MVA) viral vector-based vaccines. Methods: RNA sequencing and whole-exome sequencing were used to identify candidate tumor-associated antigens (TAAs) and neoantigens, and tumor-specific expression was validated by RT-qPCR. ChAdOx1 and MVA vectors encoding candidate antigens were generated and evaluated for immunogenicity and anti-tumor efficacy. Antigen-specific CD8+ T cell responses and minimal epitopes were characterized by ex vivo restimulation, MHC-I binding assays, tetramer staining, and tumor cytotoxicity assays. Results: We identified five candidate TAAs (Gpr149, Cdh6, Fbn2, Igf2bp1, and Shox2) but no suitable neoantigen targets in SB28. Vaccination induced CD8+ T cell responses against the candidate TAAs, and immunogenic minimal epitopes were identified for each. Among the candidates, Gpr149 elicited the strongest vaccine-induced CD8+ T cell responses. In mice challenged intracranially with SB28, Gpr149-targeted ChAdOx1/MVA vaccination combined with immune checkpoint blockade significantly prolonged median survival and resulted in long-term survival in 50% of mice, whereas vaccination targeting the other TAAs did not improve survival. CD8+ T cells recognizing the immunodominant Gpr149128-135 epitope (VCYNFYTM) specifically recognized and lysed wild-type SB28 cells, but not Gpr149-knockout SB28 cells, confirming endogenous processing and presentation of the targeted epitope. Conclusions: Gpr149 is an endogenous SB28 tumor antigen that can be effectively targeted by ChAdOx1/MVA vaccination to generate protective anti-tumor immunity against intracranial glioblastoma. Protection was associated with a dominant CD8+ T cell response to the Gpr149128-135 epitope VCYNFYTM. These findings establish endogenously expressed Gpr149 in SB28 as a physiologically relevant model for evaluating antigen-targeted immunotherapies and provide a systematic approach for identifying endogenous vaccine targets in other preclinical models.

immunology↗

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunity

Glioblastoma is a lethal brain tumor that is unresponsive to current cancer immunotherapeutic approaches, including immune checkpoint blockade (ICB). This suggests that initial priming of T cells, rather than their expansion and licensing as effectors, is a restricting feature in this tumor setting. To overcome the limited initiation of CD8+ T cell responses, we employed a strong heterologous prime-boost vaccination with the simian adenovirus ChAdOx1 and poxvirus modified vaccinia Ankara (MVA). Vaccination conferred therapeutic efficacy against orthotopic, immune checkpoint-blockade (ICB)-refractory SB28 murine glioblastoma. Vaccination was effective against both the murine tumor antigen, P1A, and a newly identified glioblastoma-associated antigen, Gpr149. Additional treatment with ICB provided no additional benefit. Systemic ChAdOx1/MVA vaccination induced robust infiltration of antigen-specific T cells in tumor-challenged brains, the majority of which exhibited a CD103+CD69+CD8+ tissue-resident memory (TRM)-like phenotype. These cells were polyfunctional, durable in brains with sustained tumor control, and mediated tissue-specific immunological memory. Moreover, intracranial adoptive transfer of glioblastoma-derived antigen-specific TRM-like cells was sufficient to protect naive recipients from subsequent orthotopic tumor challenge. Together, these findings establish that viral vector vaccination can generate tumor-specific TRM-like cells that mediate effective anti-glioblastoma immunity, providing a rationale for clinical evaluation of ChAdOx1/MVA-based strategies in glioblastoma.

immunology↗

MAIT cells and MR1 play an immunosuppressive role in glioblastoma through the induction of neutrophils and MDSCs

Glioblastoma (GBM) is the most aggressive primary brain cancer in adults and remains incurable. Our study revealed an immunosuppressive role of mucosal-associated invariant T (MAIT) cells in GBM. In bulk RNA sequencing data analysis of GBM tissues, MAIT cell gene signature significantly correlated with poor patient survival. A scRNA-seq of CD45+ cells from 23 GBM tissue samples showed 15 (65.2%) were positive for MAIT cells and the enrichment of MAIT17. The MAIT cell signature significantly correlated with the activity of tumor-associated neutrophils (TANs) and myeloid-derived suppressor cells (MDSCs). Multiple immune suppressive genes known to be used by TANs/MDSCs were upregulated in MAIT-positive tumors. Spatial imaging analysis of GBM tissues showed that all specimens were positive for both MAIT cells and TANs and localized enrichment of TANs. These findings highlight the MAIT-TAN/MDSC axis as a novel therapeutic target to modulate GBMs immunosuppressive tumor microenvironment.

immunology↗